Evidence map›Paper›PMID 34067072›Full record

ArticleInternational journal of molecular sciences2021

High Levels of the Cleaved Form of Galectin-9 and Osteopontin in the Plasma Are Associated with Inflammatory Markers That Reflect the Severity of COVID-19 Pneumonia.

Gaowa Bai, Daisuke Furushima, Toshiro Niki, Takashi Matsuba, Yosuke Maeda, Atsushi Takahashi, Toshio Hattori, Yugo Ashino

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Galectins and Liver Diseases.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Observational
  10. Article
  11. A virological view of tenascin-C in infection.American journal of physiology. Cell physiology · 2023
    Review
  12. COVID-19 Molecular Pathophysiology: Acetylation of Repurposing Drugs.International journal of molecular sciences · 2022
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Hematopoietic responses to SARS-CoV-2 infection.Cellular and molecular life sciences : CMLS · 2022
    Review
  18. Review
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Gaowa BaiResearch Institute of Health and Welfare, Kibi International University, Takahashi 716-8508, Japan.ORCID 0000-0003-4364-1134
Daisuke FurushimaDepartment of Drug Evaluation and Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka 422-8526, Japan.
Toshiro NikiDepartment of Immunology, Kagawa University, Kagawa 761-0793, Japan.ORCID 0000-0003-4531-1331
Takashi MatsubaDepartment of Microbiology and Immunology, Faculty of Medicine, Tottori University, Tottori 683-8503, Japan.
Yosuke MaedaViral Section, Department of Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Atsushi TakahashiResearch Institute of Health and Welfare, Kibi International University, Takahashi 716-8508, Japan.
Toshio HattoriResearch Institute of Health and Welfare, Kibi International University, Takahashi 716-8508, Japan.ORCID 0000-0003-0947-7625
Yugo AshinoDepartment of Respiratory Medicine, Sendai City Hospital, Miyagi 982-8502, Japan.
Kibi International University · JPKagawa University · JPKumamoto University · JPKyushu University of Health and Welfare · JPSendai City Hospital · JPUniversity of Shizuoka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Numbers of patients with coronavirus disease 2019 (COVID-19) have increased rapidly worldwide. Plasma levels of full-length galectin-9 (FL-Gal9) and osteopontin (FL-OPN) as well as their truncated forms (Tr-Gal9, Ud-OPN, respectively), are representative inflammatory biomarkers. Here, we measured FL-Gal9, FL-OPN, Tr-Gal9, and Ud-OPN in 94 plasma samples obtained from 23 COVID-19-infected patients with mild clinical symptoms (CV), 25 COVID-19 patients associated with pneumonia (CP), and 14 patients with bacterial infection (ID). The four proteins were significantly elevated in the CP group when compared with healthy individuals. ROC analysis between the CV and CP groups showed that C-reactive protein had the highest ability to differentiate, followed by Tr-Gal9 and ferritin. Spearman's correlation analysis showed that Tr-Gal9 and Ud-OPN but not FL-Gal9 and FL-OPN, had a significant association with laboratory markers for lung function, inflammation, coagulopathy, and kidney function in CP patients. CP patients treated with tocilizumab had reduced levels of FL-Gal9, Tr-Gal9, and Ud-OPN. It was suggested that OPN is cleaved by interleukin-6-dependent proteases. These findings suggest that the cleaved forms of OPN and galectin-9 can be used to monitor the severity of pathological inflammation and the therapeutic effects of tocilizumab in CP patients.

Indexed as

AdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBiomarkersCOVID-19COVID-19 Drug TreatmentFemaleGalectinsHumansInflammationKidneyMaleMiddle AgedOsteopontinPneumoniaAntibodies, Monoclonal, HumanizedBiomarkersGalectinsLGALS9 protein, humanOsteopontinSPP1 protein, humantocilizumabCOVID-19COVID pneumoniafull-length galectin-9full-length osteopontininfectious diseasesinflammatory markerstherapytocilizumabtruncated galectin-9undefined osteopontin

Identifiers

PMID34067072
PMCPMC8125627
OpenAlexW3158968304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.